Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study

A J Simpson, N A Booth, N R Moore, S J Lewis, R S Gray

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Several haemostatic abnormalities are associated with proliferative diabetic retinopathy. While abnormalities in plasma fibrinolytic activity have been described in diabetic retinopathy, platelets (a rich source of plasminogen activator inhibitor type 1, PAI-1) have received little attention. As a result, little is known about the fibrinolytic potential of circulating whole blood in diabetic retinopathy. The concentrations trations of tissue-type plasminogen activator (t-PA) and of its fast-acting inhibitor, PAI-1 were measured in plasma from eight patients with type 1 diabetes complicated by proliferative retinopathy, and from eight patients with type 1 diabetes and background or no retinopathy, matched for age, sex and duration of diabetes. The concentration of PAI-1 in platelets was also measured. The ratio of t-PA to PAI-1 in plasma was significantly higher in patients with proliferative retinopathy than in those without (0.66 vs. 0.37, p < 0.02). The average quantity of PAI-1 per platelet was significantly lower in the group with proliferative retinopathy (0.33 vs. 0.50 ng/10(6) platelets, p < 0.02). These data suggest that among patients with type 1 diabetes, total circulating fibrinolytic potential is higher in those with proliferative retinopathy.

Original languageEnglish
Pages (from-to)155-158
Number of pages4
JournalActa Diabetologica
Volume36
Publication statusPublished - 1999

Keywords

  • diabetes
  • retinopathy
  • fibrinolysis
  • plasma
  • platelets
  • FIBRINOLYTIC SYSTEM
  • HEMOSTATIC VARIABLES
  • CHRONIC SMOKING
  • MELLITUS
  • PLASMA
  • PLATELETS
  • MICROANGIOPATHY
  • COMPLICATIONS
  • NEPHROPATHY
  • ANTIGEN

Cite this

Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study. / Simpson, A J ; Booth, N A ; Moore, N R ; Lewis, S J ; Gray, R S .

In: Acta Diabetologica, Vol. 36, 1999, p. 155-158.

Research output: Contribution to journalArticle

@article{a97d8a63fc15460ca26bb2f10a25db51,
title = "Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study",
abstract = "Several haemostatic abnormalities are associated with proliferative diabetic retinopathy. While abnormalities in plasma fibrinolytic activity have been described in diabetic retinopathy, platelets (a rich source of plasminogen activator inhibitor type 1, PAI-1) have received little attention. As a result, little is known about the fibrinolytic potential of circulating whole blood in diabetic retinopathy. The concentrations trations of tissue-type plasminogen activator (t-PA) and of its fast-acting inhibitor, PAI-1 were measured in plasma from eight patients with type 1 diabetes complicated by proliferative retinopathy, and from eight patients with type 1 diabetes and background or no retinopathy, matched for age, sex and duration of diabetes. The concentration of PAI-1 in platelets was also measured. The ratio of t-PA to PAI-1 in plasma was significantly higher in patients with proliferative retinopathy than in those without (0.66 vs. 0.37, p < 0.02). The average quantity of PAI-1 per platelet was significantly lower in the group with proliferative retinopathy (0.33 vs. 0.50 ng/10(6) platelets, p < 0.02). These data suggest that among patients with type 1 diabetes, total circulating fibrinolytic potential is higher in those with proliferative retinopathy.",
keywords = "diabetes, retinopathy, fibrinolysis, plasma, platelets, FIBRINOLYTIC SYSTEM, HEMOSTATIC VARIABLES, CHRONIC SMOKING, MELLITUS, PLASMA, PLATELETS, MICROANGIOPATHY, COMPLICATIONS, NEPHROPATHY, ANTIGEN",
author = "Simpson, {A J} and Booth, {N A} and Moore, {N R} and Lewis, {S J} and Gray, {R S}",
year = "1999",
language = "English",
volume = "36",
pages = "155--158",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study

AU - Simpson, A J

AU - Booth, N A

AU - Moore, N R

AU - Lewis, S J

AU - Gray, R S

PY - 1999

Y1 - 1999

N2 - Several haemostatic abnormalities are associated with proliferative diabetic retinopathy. While abnormalities in plasma fibrinolytic activity have been described in diabetic retinopathy, platelets (a rich source of plasminogen activator inhibitor type 1, PAI-1) have received little attention. As a result, little is known about the fibrinolytic potential of circulating whole blood in diabetic retinopathy. The concentrations trations of tissue-type plasminogen activator (t-PA) and of its fast-acting inhibitor, PAI-1 were measured in plasma from eight patients with type 1 diabetes complicated by proliferative retinopathy, and from eight patients with type 1 diabetes and background or no retinopathy, matched for age, sex and duration of diabetes. The concentration of PAI-1 in platelets was also measured. The ratio of t-PA to PAI-1 in plasma was significantly higher in patients with proliferative retinopathy than in those without (0.66 vs. 0.37, p < 0.02). The average quantity of PAI-1 per platelet was significantly lower in the group with proliferative retinopathy (0.33 vs. 0.50 ng/10(6) platelets, p < 0.02). These data suggest that among patients with type 1 diabetes, total circulating fibrinolytic potential is higher in those with proliferative retinopathy.

AB - Several haemostatic abnormalities are associated with proliferative diabetic retinopathy. While abnormalities in plasma fibrinolytic activity have been described in diabetic retinopathy, platelets (a rich source of plasminogen activator inhibitor type 1, PAI-1) have received little attention. As a result, little is known about the fibrinolytic potential of circulating whole blood in diabetic retinopathy. The concentrations trations of tissue-type plasminogen activator (t-PA) and of its fast-acting inhibitor, PAI-1 were measured in plasma from eight patients with type 1 diabetes complicated by proliferative retinopathy, and from eight patients with type 1 diabetes and background or no retinopathy, matched for age, sex and duration of diabetes. The concentration of PAI-1 in platelets was also measured. The ratio of t-PA to PAI-1 in plasma was significantly higher in patients with proliferative retinopathy than in those without (0.66 vs. 0.37, p < 0.02). The average quantity of PAI-1 per platelet was significantly lower in the group with proliferative retinopathy (0.33 vs. 0.50 ng/10(6) platelets, p < 0.02). These data suggest that among patients with type 1 diabetes, total circulating fibrinolytic potential is higher in those with proliferative retinopathy.

KW - diabetes

KW - retinopathy

KW - fibrinolysis

KW - plasma

KW - platelets

KW - FIBRINOLYTIC SYSTEM

KW - HEMOSTATIC VARIABLES

KW - CHRONIC SMOKING

KW - MELLITUS

KW - PLASMA

KW - PLATELETS

KW - MICROANGIOPATHY

KW - COMPLICATIONS

KW - NEPHROPATHY

KW - ANTIGEN

M3 - Article

VL - 36

SP - 155

EP - 158

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

ER -